Skip to content
To the full analysis

Sanara MedTech Stock: Growth

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

Sanara MedTech reported $103.12M in revenue for fiscal 2025, up 19% on the prior year, up 45.9% a year on average over up to five years. That makes seven years of growth in a row.

Daily figure as of 20 Nov 2026

Revenue (Annual rate)
39.3%
per year from 2006 to 2025, per share 13%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data

Growth per Year by Period

What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.

since 2020since 2015since 2006
Revenue45.9%40.8%39.3%
Revenue per share34.5%14.2%13.0%
Earningsno datano datano data
Earnings per shareno datano datano data
Free cash flowno datano datano data
Free cash flow per shareno datano datano data

Growth Over Time

Sanara MedTech reported a loss in 19 of 20 fiscal years since 2006, most recently in 2025. In the quarter to 30 Sep 2026 revenue grew 8.0% on the prior year quarter, after an average of 13.4% in the four quarters before.

Fiscal Years at a Glance

How Revenue and Earnings Grow

  • Revenue
  • Earnings
  • Free cash flow
Figures as a table
YearRevenueEarningsFree cash flow
2006$189.76K−$623.56K−$415.4K
2007$630.51K−$542.76K−$462.55K
2008$290.18K−$1.77M−$1.06M
2009$288.02K−$2.3M−$1.3M
2010$910.42K−$5.14M−$1.28M
2011$2.21M−$12.74M−$343.6K
2012$1.17M−$1.85M−$1.23M
2013$1.73M−$4.15M−$1.85M
2014$2.63M−$2.28M−$1.69M
2015$3.37M−$1.34M−$1.21M
2016$5.51M−$415.75K$406.22K
2017$6.3M$331.31K−$225.74K
2018$5.84M−$600.57K$268.66K
2019$11.77M−$2.81M−$3.87M
2020$15.59M−$4.36M−$5.68M
2021$24.14M−$7.92M−$5.56M
2022$45.84M−$7.94M−$6.3M
2023$64.99M−$4.3M−$3.51M
2024$86.67M−$9.66M−$253.08K
2025$103.12M−$37.56M$2.16M

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.